Trial Profile

A study assessing Quetiapine Fumarate for the treatment of schizophrenia and bipolar disorder

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 12 Oct 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Quetiapine (Primary)
Indications Bipolar disorders; Schizophrenia
Focus Adverse reactions
Sponsors OWP Pharmaceuticals

Most Recent Events

12 Oct 2020 New trial record
07 Oct 2020 According to an OWP Pharmaceuticals media release, the company announced that it has received approval for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for the first-ever liquid formulation of quetiapine fumarate.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com